Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSENSE-1
2024-517677-25-00Phase 2Authorised
- Sponsor
- St. Olavs University Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by St. Olavs University Hospital. Primary endpoints: Rate of generating valid tumouroid response reports and Time from referral to start of allocated treatment. Planned start Dec 2024; status: authorised.
02
Drugs
oxaliplatinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-517677-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517677-25-00.